Issue 2/2026
Yordanova 1,2, M., Boronsuzov 1,2, Iv.
1 Clinic of Pediatric Clinical Hematology and Oncology, UMBAL “Tsarina Ioanna – ISUL”
2 Department of Pediatrics, Medical University, Sofia
Cellular immunotherapies – including chimeric antigen receptor (CAR) T cells, natural killer (NK) cells, donor-derived grafts, and tumor-infiltrating lymphocytes (TILs) as well as combination strategies that integrate antibody-based agents, inhibitory molecules, and cellular products, represent a rapidly evolving therapeutic frontier for high-risk pediatric solid tumors.
Key words: immunotherapy, cellular therapy, pediatric solid tumors
Address for correspondence:
Assoc. Prof. Dr. Maya Yordanova, MD
Clinic of Pediatric Clinical Hematology and
Oncology, UMHAT „Tsarina Ioanna – ISUL“
8, „Byalo More“, Str.
1527, Sofia